Diseases (158)
Diagnostic Testing (74)

Note:

Evaluate cardiovascular risk.


Note:

Rule out hyperlipidemia.


Note:

Patients with DM have an increased incidence of lipid abnormalities, creating risk for CVD


Note:

Can be elevated in polycysitc ovarian syndrome (PCOS).


Note:

Note:

Rule out atherosclerosis as a cause of disease.


Note:

Lipid profiles may be deranged in a patient with ACS and lend little to the immediate diagnosis.


Note:

Monitor lipids, cholesterol.


Note:

R/O pseudohyponatremia due to either elevated triglycerides or cholesterol.


Note:

Smokers usually have lower high-density lipoprotein cholesterol. Intern Med 2006;45(18):1027.

Disease Management Testing (58)

Note:

Note:

Patients with DM have an increased incidence of lipid abnormalities, creating risk for CVD


Note:

Monitor for dyslipidemia in patients receiving cyclosporin, tacrolimus, sirolimus, everolimus or prednisone


Note:

Patients should be screened annually for dyslipidemia after transplantation


Note:

If elevated, to monitor therapy.


Note:

Patients with DM have an increased incidence of lipid abnormalities, creating risk for CVD


Note:

Elevated LDL concentrations are common and may require therapy.


Note:

Evaluate for hyperlipidemia in patients treated with second generation anti-psychotics

Overview

The lipid profile, also known as the coronary risk panel, is comprised of total cholesterol, triglyceride, LDL-C (low density lipoprotein cholesterol), and HDL-C (high density lipoprotein cholesterol). It is usually used for evaluation of the risk for coronary heart disease and stroke. Testing lipid profile and especially cholesterol and cholesterol particles is the first step in screening for atherosclerosis risk, which might be the cause of heart attack and stroke. A heart attack or stroke is most commonly caused by blood vessels being blocked or by atherosclerosis (hardening of the arteries).

If through lipid testing it is discovered that a lipid disorder exists, treatments can be started to normalize lipid levels. Normalization can be achieved through medication, changes in diet, weight loss, and exercise. Therefore, this profile can be used as a screening test for risk evaluation for coronary heart disease and stroke, as well as diagnostic test for diagnosis and treatment monitoring of coronary heart disease, and familial hypercholesterolemia. It can be also used to monitor cholesterol and lipid-lowering lifestyle changes such as diet and exercise or to monitor cholesterol lowering drug therapy. Individuals with high blood pressure, tobacco smokers, individuals with a family history of cardiovascular disease, older people, and diabetes mellitus patients are at risk and should be screened. A more extended panel called NMR LipoProfile® test can be used for further screening and/or diagnosis. This test measures LDL particle number and size of LDL particles, as well as direct measurement of HDL and VLDL subclasses.

Cholesterol
Cholesterol is a steroid, a waxy substance that is found in the blood, tissues, and organs of all mammals including humans. Cholesterol is synthesized mainly in the liver. Metabolized cholesterol accounts for 75% of the cholesterol level, and diet accounts for the other 25%. Total cholesterol level in the body is dependent on many factors such as diet, liver function, lipid metabolism, heredity, and lifestyle choices. Testing serum cholesterol is the first step in screening for atherosclerosis risk.

Triglycerides
Triglycerides are stored in the fat cells of the body and serve as a main source of body energy. Triglycerides are absorbed in the intestine and are also synthesized in the liver. Elevated triglycerides are now considered an independent risk factor for coronary artery disease, and a major risk factor for acute pancreatitis, particularly when serum triglyceride levels are >1000 mg/dL.

High density lipoproteins (HDL)
HDL is responsible for the transport of cholesterol from the peripheral cells to the liver, where it is converted to bile acids which are excreted into the intestine via the biliary tract. Elevated HDL concentrations are protective against coronary heart disease, while reduced HDL concentrations indicate increased cardiovascular risk.

Low-density lipoprotein (LDL)
LDL belongs to a group of lipoproteins which serve as a transporter for cholesterol and lipids. Testing for LDL is used to evaluate the risk for coronary heart disease and stroke. High levels are associated with an increased risk of atherosclerosis and coronary heart disease and stroke.

Clinical Utility

  • Evaluate the risk for coronary heart disease
  • Diagnosis of Atherosclerosis (arteriosclerotic vascular disease)
  • Diagnosis of familial hypercholesterolemia
  • Used to evaluate the effectiveness of drug therapy (cholesterol lowering drugs)
  • As an aid in evaluation of diabetes mellitus, nephrotic syndrome, and liver disease with biliary obstruction
  • As an aid in evaluation of fatty liver in chronic alcoholism
  • As an aid in diagnosis of lipoproteinemia due to lipase deficiency
  • Monitoring drug treatment therapy

Interpretation

Increased in:

  • Coronary heart disease and stroke
  • Familial hypercholesterolemia
  • Familial combined hyperlipidemia
  • Atherosclerotic coronary artery disease
  • Hypertension
  • Hypothyroidism
  • Uncontrolled diabetes mellitus
  • Nephrotic syndrome
  • Liver disorders such as biliary obstruction and hepatocellular carcinoma
  • Cushing’s syndrome
  • Acute intermittent porphyria
  • Chronic alcoholism (fatty liver)
  • Biliary tract obstruction
  • Familial lipoprotein lipase deficiency
  • Familial dysbetalipoproteinemia
  • Obesity
  • Use of corticosteroids

Decreased in:

  • Severe liver disease (acute hepatitis, cirrhosis, malignancy)
  • Hyperthyroidism
  • Severe, acute, or chronic illness
  • Malnutrition and malabsorption
  • Extensive burns
  • Gaucher’s disease
  • Tangier disease (lipoprotein deficiency)
  • Hypolipoproteinemia and abetalipoproteinemia
  • Malnutrition
  • Decreased in use of some drugs such as: ascorbic acid, clofibrate, nicotinic acid, gemfibrozil

Reference Ranges

Element Optimal Borderline High risk
LDL Cholesterol <100 130-159 160+
HDL Cholesterol >60 35-45 <35
Triglycerides <150 150-199 >200
Total Cholesterol <200 200-239 >240
Cholesterol:HDL Ratio <4 5 >6



Methodology

RIA (Radioimmunoassay), ELISA (Enzyme-Linked Immunosorbent Assay), RID (Radial ImmunoDiffusion), Enzymatic, Colorimetric methods to separate LDL, HDL and Triglycerides. Refer to individual laboratory methods.

Specimen Collection

Serum (SST)

Red top acceptable. 1 mL minimum. 12 hour fasting. No alcohol 24 hours prior to draw.

Stability:

  • Ambient: 48 hours
  • Refrigerated: 7 days
  • Frozen: 30 days

Additional Testing

Apolipoprotein A-I, Apolipoprotein B-100, C-reactive protein (CRP), Homocysteine, VLDL-C (very low density lipoprotein cholesterol), NMR Lipo profile, Liver panel, Comprehensive metabolic panel, CBC.

CPT
80061$13.39$13.39
82465$4.35$4.35

ICD10
  • AK - Alaska
  • AL - Alabama
  • AR - Arkansas
  • AS - American Samoa
  • AZ - Arizona
  • CA - California - Entire State
  • CO - Colorado
  • CT - Connecticut
  • DC - District of Columbia
  • DE - Delaware
  • FL - Florida
  • GA - Georgia
  • GU - Guam
  • HI - Hawaii
  • IA - Iowa
  • ID - Idaho
  • IL - Illinois
  • IN - Indiana
  • KS - Kansas
  • KY - Kentucky
  • LA - Louisiana
  • MA - Massachusetts
  • MD - Maryland
  • ME - Maine
  • MI - Michigan
  • MN - Minnesota
  • MO - Missouri - Entire State
  • MS - Mississippi
  • MT - Montana
  • NC - North Carolina
  • ND - North Dakota
  • NE - Nebraska
  • NH - New Hampshire
  • NJ - New Jersey
  • NM - New Mexico
  • NV - Nevada
  • NY - New York - Entire State
  • OH - Ohio
  • OK - Oklahoma
  • OR - Oregon
  • PA - Pennsylvania
  • PR - Puerto Rico
  • RI - Rhode Island
  • SC - South Carolina
  • SD - South Dakota
  • TN - Tennessee
  • TX - Texas
  • UT - Utah
  • VA - Virginia
  • VI - Virgin Islands
  • VT - Vermont
  • WA - Washington
  • WI - Wisconsin
  • WV - West Virginia
  • WY - Wyoming
  • CNMI - Northern Mariana Islands
  • EM - Missouri - Northeastern & Southern
  • WM - Missouri - Northwestern
  • DN - New York - Downstate
  • QN - New York - Queens
  • UN - New York - Upstate
  • NF - California - Northern
  • SF - California - Southern
Showing results for all states.
Filter:
ICD10 CODE AND DESCRIPTIONLCD CODENCD CODE
B15 - Acute hepatitis A
B16 - Acute hepatitis B
B16.1 - Acute hepatitis B with delta-agent without hepatic coma
B17.1 - Acute hepatitis C
B17.10 - Acute hepatitis C without hepatic coma
B17.2 - Acute hepatitis E
B19.20 - Unspecified viral hepatitis C without hepatic coma
B20 - Human immunodeficiency virus [HIV] disease
B97.35 - Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere
C25 - Malignant neoplasm of pancreas
C74 - Malignant neoplasm of adrenal gland
C74.0 - Malignant neoplasm of cortex of adrenal gland
C74.00 - Malignant neoplasm of cortex of unspecified adrenal gland
C74.01 - Malignant neoplasm of cortex of right adrenal gland
C74.02 - Malignant neoplasm of cortex of left adrenal gland
C74.1 - Malignant neoplasm of medulla of adrenal gland
C74.10 - Malignant neoplasm of medulla of unspecified adrenal gland
C74.11 - Malignant neoplasm of medulla of right adrenal gland
C74.12 - Malignant neoplasm of medulla of left adrenal gland
C74.9 - Malignant neoplasm of unspecified part of adrenal gland
C74.90 - Malignant neoplasm of unspecified part of unspecified adrenal gland
C74.91 - Malignant neoplasm of unspecified part of right adrenal gland
C74.92 - Malignant neoplasm of unspecified part of left adrenal gland
C79.70 - Secondary malignant neoplasm of unspecified adrenal gland
C79.71 - Secondary malignant neoplasm of right adrenal gland
C79.72 - Secondary malignant neoplasm of left adrenal gland
D13 - Benign neoplasm of other and ill-defined parts of digestive system
D13.6 - Benign neoplasm of pancreas
D35 - Benign neoplasm of other and unspecified endocrine glands
D35.0 - Benign neoplasm of adrenal gland
D35.00 - Benign neoplasm of unspecified adrenal gland
D35.2 - Benign neoplasm of pituitary gland
D3A - Benign neuroendocrine tumors
D3A.8 - Other benign neuroendocrine tumors
D49 - Neoplasms of unspecified behavior
D49.7 - Neoplasm of unspecified behavior of endocrine glands and other parts of nervous system
D63 - Anemia in chronic diseases classified elsewhere
D63.1 - Anemia in chronic kidney disease
D68.9 - Coagulation defect, unspecified
E00 - Congenital iodine-deficiency syndrome
E00.9 - Congenital iodine-deficiency syndrome, unspecified
E01 - Iodine-deficiency related thyroid disorders and allied conditions
E01.0 - Iodine-deficiency related diffuse (endemic) goiter
E02 - Subclinical iodine-deficiency hypothyroidism
E03 - Other hypothyroidism
E03.0 - Congenital hypothyroidism with diffuse goiter
E03.1 - Congenital hypothyroidism without goiter
E03.2 - Hypothyroidism due to medicaments and other exogenous substances
E03.3 - Postinfectious hypothyroidism
E03.8 - Other specified hypothyroidism

Additional ICD10
  • AK - Alaska
  • AL - Alabama
  • AR - Arkansas
  • AS - American Samoa
  • AZ - Arizona
  • CA - California - Entire State
  • CO - Colorado
  • CT - Connecticut
  • DC - District of Columbia
  • DE - Delaware
  • FL - Florida
  • GA - Georgia
  • GU - Guam
  • HI - Hawaii
  • IA - Iowa
  • ID - Idaho
  • IL - Illinois
  • IN - Indiana
  • KS - Kansas
  • KY - Kentucky
  • LA - Louisiana
  • MA - Massachusetts
  • MD - Maryland
  • ME - Maine
  • MI - Michigan
  • MN - Minnesota
  • MO - Missouri - Entire State
  • MS - Mississippi
  • MT - Montana
  • NC - North Carolina
  • ND - North Dakota
  • NE - Nebraska
  • NH - New Hampshire
  • NJ - New Jersey
  • NM - New Mexico
  • NV - Nevada
  • NY - New York - Entire State
  • OH - Ohio
  • OK - Oklahoma
  • OR - Oregon
  • PA - Pennsylvania
  • PR - Puerto Rico
  • RI - Rhode Island
  • SC - South Carolina
  • SD - South Dakota
  • TN - Tennessee
  • TX - Texas
  • UT - Utah
  • VA - Virginia
  • VI - Virgin Islands
  • VT - Vermont
  • WA - Washington
  • WI - Wisconsin
  • WV - West Virginia
  • WY - Wyoming
  • CNMI - Northern Mariana Islands
  • EM - Missouri - Northeastern & Southern
  • WM - Missouri - Northwestern
  • DN - New York - Downstate
  • QN - New York - Queens
  • UN - New York - Upstate
  • NF - California - Northern
  • SF - California - Southern
Showing results for all states.
Filter:
ICD10 CODE AND DESCRIPTIONLCD CODENCD CODE
A02.25 - Salmonella pyelonephritis
A36.81 - Diphtheritic cardiomyopathy
A51.44 - Secondary syphilitic nephritis
A52.04 - Syphilitic cerebral arteritis
B15.0 - Hepatitis A with hepatic coma
B15.9 - Hepatitis A without hepatic coma
B16.0 - Acute hepatitis B with delta-agent with hepatic coma
B16.1 - Acute hepatitis B with delta-agent without hepatic coma
B16.2 - Acute hepatitis B without delta-agent with hepatic coma
B16.9 - Acute hepatitis B without delta-agent and without hepatic coma
B18.0 - Chronic viral hepatitis B with delta-agent
B18.1 - Chronic viral hepatitis B without delta-agent
B18.2 - Chronic viral hepatitis C
B19.0 - Unspecified viral hepatitis with hepatic coma
B19.1 - Unspecified viral hepatitis B
B19.10 - Unspecified viral hepatitis B without hepatic coma
B19.11 - Unspecified viral hepatitis B with hepatic coma
B19.2 - Unspecified viral hepatitis C
B19.20 - Unspecified viral hepatitis C without hepatic coma
B19.21 - Unspecified viral hepatitis C with hepatic coma
B19.9 - Unspecified viral hepatitis without hepatic coma
B25.2 - Cytomegaloviral pancreatitis
B26.3 - Mumps pancreatitis
B26.83 - Mumps nephritis
B33.24 - Viral cardiomyopathy
C25.0 - Malignant neoplasm of head of pancreas
C25.1 - Malignant neoplasm of body of pancreas
C25.2 - Malignant neoplasm of tail of pancreas
C25.3 - Malignant neoplasm of pancreatic duct
C25.4 - Malignant neoplasm of endocrine pancreas
C25.7 - Malignant neoplasm of other parts of pancreas
C25.8 - Malignant neoplasm of overlapping sites of pancreas
C25.9 - Malignant neoplasm of pancreas, unspecified
C74.0 - Malignant neoplasm of cortex of adrenal gland
C74.00 - Malignant neoplasm of cortex of unspecified adrenal gland
C74.01 - Malignant neoplasm of cortex of right adrenal gland
C74.02 - Malignant neoplasm of cortex of left adrenal gland
C74.1 - Malignant neoplasm of medulla of adrenal gland
C74.10 - Malignant neoplasm of medulla of unspecified adrenal gland
C74.11 - Malignant neoplasm of medulla of right adrenal gland
C74.12 - Malignant neoplasm of medulla of left adrenal gland
C74.9 - Malignant neoplasm of unspecified part of adrenal gland
C74.90 - Malignant neoplasm of unspecified part of unspecified adrenal gland
C74.91 - Malignant neoplasm of unspecified part of right adrenal gland
C74.92 - Malignant neoplasm of unspecified part of left adrenal gland
D13.0 - Benign neoplasm of esophagus
D13.1 - Benign neoplasm of stomach
D13.2 - Benign neoplasm of duodenum
D13.3 - Benign neoplasm of other and unspecified parts of small intestine
D13.30 - Benign neoplasm of unspecified part of small intestine

References

  • J Atheroscler Thromb. 2011 Nov 30. [PMID:22129522]
  • Cardiovasc Intervent Radiol. 2007 Mar-Apr;30(2):155-60. [PMID:17206389]
  • JAMA. 2001 May 16;285(19):2486-97. [PMID:11368702]
  • Compr Ther. 1996 Aug;22(8):492-500. [PMID:8879916]
  • Geriatr Nurs. 2006 May-Jun;27(3):142-8. [PMID:16757384]
  • J Am Acad Nurse Pract. 2003 Aug;15(8):350-60. [PMID:14509100]
  • Mayo Clinic Proc. 2006;81:1225. [PMID:16970219]
  • Med Gen Med. 2006;8:54. [PMID:16915184]
  • Curr Atheroscler Rep. 2001 Sep;3(5):404-11. [PMID:11565569]
  • Clin Chem Lab Med. 2000 Apr;38(4):287-300. [PMID:10928647]
  • Endocrinol Metab Clin North Am. 2009 Mar;38(1):137-49. [PMID:19217516]
  • Am J Med Sci. 2005;330:295. [PMID:16355014]
  • Pagana K, Pagana T. Mosby's Manual of Diagnostic and Laboratory Tests. 3rd Edition, St. Louis: Mosby Elsevier (2006). Pp. 351-356
  • Jacobs DS, DeMott WR, Oxley DK. Laboratory Test Handbook, fifth edition, Lexi-COMP, Inc (2004). Pp. 212-213.